Top

Published in:

25-07-2022 | Cardiomyopathy

Cardiac Remodelling Following Cancer Therapy: A Review

Authors: Tan Panpan, Du Yuchen, Shi Xianyong, Liu Meng, He Ruijuan, Dong Ranran, Zhang Pengyan, Li Mingxi, Xie Rongrong

Published in: Cardiovascular Toxicology | Issue 9/2022

Abstract

Cardiac remodelling is characterized by abnormal changes in the function and morphological properties such as diameter, mass, normal diameter of cavities, heart shape, fibrosis, thickening of vessels and heart layers, cardiomyopathy, infiltration of inflammatory cells, and some others. These damages are associated with damage to systolic and diastolic abnormalities, damage to ventricular function, and vascular remodelling, which may lead to heart failure and death. Exposure of the heart to radiation or anti-cancer drugs including chemotherapy drugs such as doxorubicin, receptor tyrosine kinase inhibitors (RTKIs) such as imatinib, and immune checkpoint inhibitors (ICIs) can induce several abnormal changes in the heart structure and function through the induction of inflammation and fibrosis, vascular remodelling, hypertrophy, and some others. This review aims to explain the basic mechanisms behind cardiac remodelling following cancer therapy by different anti-cancer modalities.

Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., et al. (2021). Cancer statistics for the year 2020: An overview. International Journal of Cancer, 149(4), 778–789.CrossRef

Liu, Y.-Q., Wang, X.-L., He, D.-H., & Cheng, Y.-X. (2021). Protection against chemotherapy-and radiotherapy-induced side effects: A review based on the mechanisms and therapeutic opportunities of phytochemicals. Phytomedicine, 80, 153402.PubMedCrossRef

Minami, M., Matsumoto, S., & Horiuchi, H. (2010). Cardiovascular side-effects of modern cancer therapy. Circulation Journal, 2010, 1008100855.

Perez, I. E., Taveras Alam, S., Hernandez, G. A., & Sancassani, R. (2019). Cancer therapy-related cardiac dysfunction: An overview for the clinician. Clinical Medicine Insights: Cardiology, 13, 1179546819866445.PubMedPubMedCentral

Chen, D.-Y., Huang, W.-K., Wu, V.C.-C., Chang, W.-C., Chen, J.-S., Chuang, C.-K., et al. (2020). Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. Journal of the Formosan Medical Association., 119(10), 1461–75.PubMedCrossRef

Zagar, T. M., Cardinale, D. M., & Marks, L. B. (2016). Breast cancer therapy-associated cardiovascular disease. Nature Reviews Clinical Oncology., 13(3), 172–184.PubMedCrossRef

Boopathi, E., & Thangavel, C. (2021). Dark side of cancer therapy: Cancer Treatment-induced cardiopulmonary inflammation, fibrosis, and immune modulation. International Journal of Molecular Sciences, 22(18), 10126.PubMedPubMedCentralCrossRef

Du, X. L., Xia, R., Liu, C. C., Cormier, J. N., Xing, Y., Hardy, D., et al. (2009). Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer, 115(22), 5296–5308.PubMedCrossRef

Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., et al. (2010). Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology, 55(3), 213–220.PubMedCrossRef

10.

Grover, S. P., Hisada, Y. M., Kasthuri, R. S., Reeves, B. N., & Mackman, N. (2021). Cancer therapy-associated thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 41(4), 1291–1305.PubMedPubMedCentralCrossRef

11.

Galvano, A., Guarini, A., Iacono, F., Castiglia, M., Rizzo, S., Tarantini, L., et al. (2019). An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. Expert Opinion on Drug Safety., 18(6), 485–496.PubMedCrossRef

12.

Azevedo, P. S., Polegato, B. F., Minicucci, M. F., Paiva, S. A. R., & Zornoff, L. A. M. (2016). Cardiac remodeling: Concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment. Arquivos brasileiros de cardiologia., 106(1), 62–69. https://doi.org/10.5935/abc.20160005CrossRefPubMedPubMedCentral

13.

Hochman, J. S., & Bulkley, B. H. (1982). Expansion of acute myocardial infarction: An experimental study. Circulation, 65(7), 1446–1450.PubMedCrossRef

14.

Liu, L., & Eisen, H. J. (2014). Epidemiology of heart failure and scope of the problem. Cardiology Clinics, 32(1), 1–8. https://doi.org/10.1016/j.ccl.2013.09.009CrossRefPubMed

15.

Dorn, G. W., 2nd. (2009). Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovascular Research, 81(3), 465–473. https://doi.org/10.1093/cvr/cvn243CrossRefPubMed

16.

Yang, R., Tan, C., & Najafi, M. (2021). Cardiac inflammation and fibrosis following chemo/radiation therapy: Mechanisms and therapeutic agents. Inflammopharmacology. https://doi.org/10.1007/s10787-021-00894-9CrossRefPubMedPubMedCentral

17.

Lu, M., Qin, X., Yao, J., Yang, Y., Zhao, M., & Sun, L. (2020). Th17/Treg imbalance modulates rat myocardial fibrosis and heart failure by regulating LOX expression. Acta Physiologica, 230(3), e13537.PubMedCrossRef

18.

Shao, P.-P., Liu, C.-J., Xu, Q., Zhang, B., Li, S.-H., Wu, Y., et al. (2018). Eplerenone reverses cardiac fibrosis via the suppression of tregs by inhibition of Kv1. 3 channel. Frontiers in Physiology, 9, 899.PubMedPubMedCentralCrossRef

19.

Fung, T. H., Yang, K. Y., & Lui, K. O. (2020). An emerging role of regulatory T-cells in cardiovascular repair and regeneration. Theranostics, 10(20), 8924.PubMedPubMedCentralCrossRef

20.

Frieler, R. A., & Mortensen, R. M. (2015). Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation, 131(11), 1019–1030. https://doi.org/10.1161/circulationaha.114.008788CrossRefPubMedPubMedCentral

21.

Xiao, H., Li, H., Wang, J.-J., Zhang, J.-S., Shen, J., An, X.-B., et al. (2018). IL-18 cleavage triggers cardiac inflammation and fibrosis upon β-adrenergic insult. European Heart Journal, 39(1), 60–69.PubMedCrossRef

22.

Fu, X., Tang, J., Wen, P., Huang, Z., & Najafi, M. (2021). Redox interactions-induced cardiac toxicity in cancer therapy. Archives of Biochemistry and Biophysics, 708, 108952. https://doi.org/10.1016/j.abb.2021.108952CrossRefPubMed

23.

Hori, M., & Nishida, K. (2009). Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovascular Research, 81(3), 457–464.PubMedCrossRef

24.

Briasoulis, A., Androulakis, E., Christophides, T., & Tousoulis, D. (2016). The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Failure Reviews, 21(2), 169–176.PubMedCrossRef

25.

Grover, S., Lou, P., Bradbrook, C., Cheong, K., Kotasek, D., Leong, D., et al. (2015). Early and late changes in markers of aortic stiffness with breast cancer therapy. Internal Medicine Journal, 45(2), 140–147.PubMedCrossRef

26.

Raghunathan, D., Khilji, M. I., Hassan, S. A., & Yusuf, S. W. (2017). Radiation-induced cardiovascular disease. Current Atherosclerosis Reports, 19(5), 22.PubMedCrossRef

27.

Yusuf, S. W., Venkatesulu, B. P., Mahadevan, L. S., & Krishnan, S. (2017). Radiation-induced cardiovascular disease: A clinical perspective. Frontiers in Cardiovascular Medicine., 4, 66.PubMedPubMedCentralCrossRef

28.

Oun, R., & Rowan, E. (2017). Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node? European Journal of Pharmacology, 811, 125–128.PubMedCrossRef

29.

Patanè, S. (2014). Cardiotoxicity: Cisplatin and long-term cancer survivors. International Journal of Cardiology., 175(1), 201–202.PubMedCrossRef

30.

Hilmi, M., Ederhy, S., Waintraub, X., Funck-Brentano, C., Cohen, A., Vozy, A., et al. (2020). Cardiotoxicity associated with gemcitabine: Literature review and a pharmacovigilance study. Pharmaceuticals, 13(10), 325. https://doi.org/10.3390/ph13100325CrossRefPubMedCentral

31.

Sara, J. D., Kaur, J., Khodadadi, R., Rehman, M., Lobo, R., Chakrabarti, S., et al. (2018). 5-fluorouracil and cardiotoxicity: A review. Therapeutic Advances in Medical Oncology, 10, 1758835918780140. https://doi.org/10.1177/1758835918780140CrossRefPubMedPubMedCentral

32.

Mizia-Stec, K., Gościńska, A., Mizia, M., Haberka, M., Chmiel, A., Poborski, W., et al. (2013). Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling. Kardiologia Polska, 71(7), 681–690.PubMedCrossRef

33.

Lupón, J., Gavidia-Bovadilla, G., Ferrer, E., de Antonio, M., Perera-Lluna, A., López-Ayerbe, J., et al. (2018). Dynamic trajectories of left ventricular ejection fraction in heart failure. Journal of the American College of Cardiology., 72(6), 591–601.PubMedCrossRef

34.

Kumar, S., Marfatia, R., Tannenbaum, S., Yang, C., & Avelar, E. (2012). Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. Texas Heart Institute Journal., 39(3), 424.PubMedPubMedCentral

35.

Trapani, D., Zagami, P., Nicolò, E., Pravettoni, G., & Curigliano, G. (2020). Management of cardiac toxicity induced by chemotherapy. Journal of Clinical Medicine., 9(9), 2885.PubMedCentralCrossRef

36.

Hu, J.-R., Florido, R., Lipson, E. J., Naidoo, J., Ardehali, R., Tocchetti, C. G., et al. (2019). Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovascular Research., 115(5), 854–868.PubMedPubMedCentralCrossRef

37.

Wu, Q.-Q., Xiao, Y., Yuan, Y., Ma, Z.-G., Liao, H.-H., Liu, C., et al. (2017). Mechanisms contributing to cardiac remodelling. Clinical Science., 131(18), 2319–2345.PubMedCrossRef

38.

Mortezaee, K., & Najafi, M. (2021). Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives. Critical Reviews in Oncology/Hematology., 157, 103180.PubMedCrossRef

39.

Chitturi, K. R., Araujo-Gutierrez, R., McLean, E. T., Xu, J., Bhimaraj, A., Guha, A., et al. (2019). Cardiotoxicity of immune checkpoint inhibitors in patients with lung cancer. Journal of Cardiac Failure, 25(8), S50. https://doi.org/10.1016/j.cardfail.2019.07.141CrossRef

40.

Michel, L., Totzeck, M., Lehmann, L., & Finke, D. (2020). Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system. Herz, 45(7), 645–651. https://doi.org/10.1007/s00059-020-04954-8CrossRefPubMed

41.

Ranpura, V., Hapani, S., Chuang, J., & Wu, S. (2010). Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncologica, 49(3), 287–297.PubMedCrossRef

42.

Economopoulou, P., Kotsakis, A., Kapiris, I., & Kentepozidis, N. (2015). Cancer therapy and cardiovascular risk: Focus on bevacizumab. Cancer Management and Research, 7, 133.PubMedPubMedCentralCrossRef

43.

Ghatalia, P., Morgan, C. J., Je, Y., Nguyen, P. L., Trinh, Q.-D., Choueiri, T. K., et al. (2015). Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology, 94(2), 228–237.PubMedCrossRef

44.

Khakoo, A. Y., Kassiotis, C. M., Tannir, N., Plana, J. C., Halushka, M., Bickford, C., et al. (2008). Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer: Interdisciplinary International Journal of the American Cancer Society., 112(11), 2500–2508.CrossRef

45.

Pentassuglia, L., Graf, M., Lane, H., Kuramochi, Y., Cote, G., Timolati, F., et al. (2009). Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Experimental Cell Research., 315(7), 1302–1312.PubMedPubMedCentralCrossRef

46.

Farhood, B., Goradel, N. H., Mortezaee, K., Khanlarkhani, N., Salehi, E., Nashtaei, M. S., et al. (2019). Intercellular communications-redox interactions in radiation toxicity; potential targets for radiation mitigation. Journal of Cell Communication and Signaling., 13(1), 3–16. https://doi.org/10.1007/s12079-018-0473-3CrossRefPubMed

47.

Harel, S., Mayaki, D., Sanchez, V., & Hussain, S. N. (2017). NOX2, NOX4, and mitochondrial-derived reactive oxygen species contribute to angiopoietin-1 signaling and angiogenic responses in endothelial cells. Vascular Pharmacology, 92, 22–32.PubMedCrossRef

48.

Navarro-Yepes, J., Burns, M., Anandhan, A., Khalimonchuk, O., Del Razo, L. M., Quintanilla-Vega, B., et al. (2014). Oxidative stress, redox signaling, and autophagy: Cell death versus survival. Antioxidants & Redox Signaling., 21(1), 66–85.CrossRef

49.

Livingston, K., Schlaak, R. A., Puckett, L. L., & Bergom, C. (2020). The role of mitochondrial dysfunction in radiation-induced heart disease: From bench to bedside. Frontiers in Cardiovascular Medicine., 7, 20. https://doi.org/10.3389/fcvm.2020.00020CrossRefPubMedPubMedCentral

50.

Panganiban, R. A., Mungunsukh, O., & Day, R. M. (2013). X-irradiation induces ER stress, apoptosis, and senescence in pulmonary artery endothelial cells. International Journal of Radiation Biology, 89(8), 656–667. https://doi.org/10.3109/09553002.2012.711502CrossRefPubMed

51.

Palaskas, N., Patel, A., & Yusuf, S. W. (2019). Radiation and cardiovascular disease. Annals of Translational Medicine S371.

52.

Wang, B., Wang, H., Zhang, M., Ji, R., Wei, J., Xin, Y., et al. (2020). Radiation-induced myocardial fibrosis: Mechanisms underlying its pathogenesis and therapeutic strategies. Journal of Cellular and Molecular Medicine, 24(14), 7717–7729.PubMedPubMedCentralCrossRef

53.

Arola, O. J., Saraste, A., Pulkki, K., Kallajoki, M., Parvinen, M., & Voipio-Pulkki, L.-M. (2000). Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Research, 60(7), 1789–1792.PubMed

54.

Dhingra, R., Margulets, V., Chowdhury, S. R., Thliveris, J., Jassal, D., Fernyhough, P., et al. (2014). Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling. Proceedings of the National Academy of Sciences., 111(51), E5537–E5544.CrossRef

55.

Ashrafizadeh, M., Farhood, B., Eleojo Musa, A., Taeb, S., & Najafi, M. (2020). Damage-associated molecular patterns in tumor radiotherapy. International Immunopharmacology., 86, 106761. https://doi.org/10.1016/j.intimp.2020.106761CrossRefPubMed

56.

Yahyapour, R., Motevaseli, E., Rezaeyan, A., Abdollahi, H., Farhood, B., Cheki, M., et al. (2018). Mechanisms of radiation bystander and non-targeted effects: Implications to radiation carcinogenesis and radiotherapy. Current Radiopharmaceuticals, 11(1), 34–45. https://doi.org/10.2174/1874471011666171229123130CrossRefPubMed

57.

Farhood, B., Ashrafizadeh, M., Hoseini-Ghahfarokhi, M., Afrashi, S., Musa, A. E., & Najafi, M. (2020). Targeting of cellular redox metabolism for mitigation of radiation injury. Life Sciences., 250, 117570.PubMedCrossRef

58.

Wijerathne, H., Langston, J., Yang, Q., Sun, S., Miyamoto, C., Kilpatrick, L. E., et al. (2021). Mechanisms of radiation-induced endothelium damage: Emerging models and technologies. Radiotherapy and Oncology., 158, 21–32.PubMedPubMedCentralCrossRef

59.

Chiabrando, J. G., Bonaventura, A., Vecchié, A., Wohlford, G. F., Mauro, A. G., Jordan, J. H., et al. (2020). Management of acute and recurrent pericarditis: JACC state-of-the-art review. Journal of the American College of Cardiology., 75(1), 76–92. https://doi.org/10.1016/j.jacc.2019.11.021CrossRefPubMed

60.

Chang, A., Nasti, T. H., Khan, M. K., Parashar, S., Kaufman, J. L., Boise, L. H., et al. (2018). Myocarditis with radiotherapy and immunotherapy in multiple myeloma. Journal of Oncology Practice., 14(9), 561–564. https://doi.org/10.1200/JOP.18.00208CrossRefPubMed

61.

Tada, Y., & Suzuki, J.-I. (2016). Oxidative stress and myocarditis. Current Pharmaceutical Design., 22(4), 450–71.PubMedCrossRef

62.

Bagchi, A. K., Malik, A., Akolkar, G., Jassal, D. S., & Singal, P. K. (2021). Endoplasmic reticulum stress promotes iNOS/NO and influences inflammation in the development of doxorubicin-induced cardiomyopathy. Antioxidants., 10(12), 1897.PubMedPubMedCentralCrossRef

63.

Mortezaee, K., Najafi, M., Farhood, B., Ahmadi, A., Shabeeb, D., & Musa, A. E. (2019). NF-κB targeting for overcoming tumor resistance and normal tissues toxicity. Journal of Cellular Physiology., 234(10), 17187–17204. https://doi.org/10.1002/jcp.28504CrossRefPubMed

64.

Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., et al. (2018). Myocarditis in patients treated with immune checkpoint inhibitors. Journal of the American College of Cardiology., 71(16), 1755–1764.PubMedPubMedCentralCrossRef

65.

Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., et al. (2016). Fulminant myocarditis with combination immune checkpoint blockade. New England Journal of Medicine., 375(18), 1749–1755.PubMedCrossRef

66.

Ji, C., Roy, M. D., Golas, J., Vitsky, A., Ram, S., Kumpf, S. W., et al. (2019). Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors. Clinical Cancer Research., 25(15), 4735–4748.PubMedCrossRef

67.

Berner, A., Sharma, A., Agarwal, S., Al-Sam, S., & Nathan, P. (2018). Fatal autoimmune myocarditis with anti–PD-L1 and tyrosine kinase inhibitor therapy for renal cell cancer. European Journal of Cancer., 101, 287–290.PubMedCrossRef

68.

Burke, M. J., Walmsley, R., Munsey, T. S., & Smith, A. J. (2019). Receptor tyrosine kinase inhibitors cause dysfunction in adult rat cardiac fibroblasts in vitro. Toxicology in Vitro., 58, 178–186.PubMedCrossRef

69.

Rocca, C., De Francesco, E. M., Pasqua, T., Granieri, M. C., De Bartolo, A., Gallo Cantafio, M. E., et al. (2022). Mitochondrial determinants of anti-cancer drug-induced cardiotoxicity. Biomedicines., 10(3), 520.PubMedPubMedCentralCrossRef

70.

Truell, J. S., Fishbein, M. C., & Figlin, R. (2005). Myocarditis temporally related to the use of gefitinib (Iressa). Archives of Pathology & Laboratory Medicine., 129(8), 1044–1046.CrossRef

71.

Rezaeyan, A., Haddadi, G. H., Hosseinzadeh, M., Moradi, M., & Najafi, M. (2016). Radioprotective effects of hesperidin on oxidative damages and histopathological changes induced by X-irradiation in rats heart tissue. Journal of Medical Physics., 41(3), 182–191. https://doi.org/10.4103/0971-6203.189482CrossRefPubMedPubMedCentral

72.

Najafi, M., Shirazi, A., Motevaseli, E., Rezaeyan, A. H., Salajegheh, A., & Rezapoor, S. (2017). Melatonin as an anti-inflammatory agent in radiotherapy. Inflammopharmacology, 25(4), 403–413. https://doi.org/10.1007/s10787-017-0332-5CrossRefPubMed

73.

Najafi, M., Motevaseli, E., Geraily, G., Norouzi, F., Heidari, M., & Rezapoor, S. (2017). The melatonin immunomodulatory actions in radiotherapy. Biophysical Reviews, 9(2), 139–148.PubMedPubMedCentralCrossRef

74.

Gürses, İ, Özeren, M., Serin, M., Yücel, N., & Erkal, H. Ş. (2014). Histopathological evaluation of melatonin as a protective agent in heart injury induced by radiation in a rat model. Pathology—Research and Practice, 210(12), 863–871. https://doi.org/10.1016/j.prp.2014.08.006CrossRefPubMed

75.

Farhood, B., Aliasgharzadeh, A., Amini, P., Saffar, H., Motevaseli, E., Rezapoor, S., et al. (2019). Radiation-induced dual oxidase upregulation in rat heart tissues: Protective effect of melatonin. Medicina, 55(7), 317. https://doi.org/10.3390/medicina55070317CrossRefPubMedCentral

76.

Dhingra, A., Jayas, R., Afshar, P., Guberman, M., Maddaford, G., Gerstein, J., et al. (2017). Ellagic acid antagonizes Bnip3-mediated mitochondrial injury and necrotic cell death of cardiac myocytes. Free Radical Biology and Medicine, 112, 411–422. https://doi.org/10.1016/j.freeradbiomed.2017.08.010CrossRefPubMed

77.

Gurses, I., Ozeren, M., Serin, M., Yucel, N., & Erkal, H. S. (2018). Histopathological efficiency of amifostine in radiationinduced heart disease in rats. Bratislavske Lekarske Listy, 119(1), 54–59. https://doi.org/10.4149/bll_2018_011CrossRefPubMed

78.

Kolivand, S., Amini, P., Saffar, H., Rezapoor, S., Motevaseli, E., Najafi, M., et al. (2019). Evaluating the radioprotective effect of curcumin on rat’s heart tissues. Current Radiopharmaceuticals, 12(1), 23–28. https://doi.org/10.2174/1874471011666180831101459CrossRefPubMed

79.

Yahyapour, R., Amini, P., Saffar, H., Rezapoor, S., Motevaseli, E., Cheki, M., et al. (2018). Metformin protects against radiation-induced heart injury and attenuates the upregulation of dual oxidase genes following Rat’s chest irradiation. International Journal of Molecular and Cellular Medicine, 7(3), 193–202. https://doi.org/10.22088/IJMCM.BUMS.7.3.193CrossRefPubMedPubMedCentral

80.

Kolivand, S., Amini, P., Saffar, H., Rezapoor, S., Najafi, M., Motevaseli, E., et al. (2019). Selenium-L-methionine modulates radiation injury and Duox1 and Duox2 upregulation in rat’s heart tissues. Journal of Cardiovascular and Thoracic Research, 11(2), 121–126. https://doi.org/10.15171/jcvtr.2019.21CrossRefPubMedPubMedCentral

81.

Yang, C.-M., Lee, I.-T., Hsu, R.-C., Chi, P.-L., & Hsiao, L.-D. (2013). NADPH oxidase/ROS-dependent PYK2 activation is involved in TNF-α-induced matrix metalloproteinase-9 expression in rat heart-derived H9c2 cells. Toxicology and Applied Pharmacology, 272(2), 431–442.PubMedCrossRef

82.

Mann, D. L., & Spinale, F. G. (1998). Activation of matrix metalloproteinases in the failing human heart: Breaking the tie that binds. Circulation, 98(17), 1699–1702.PubMedCrossRef

83.

Kizaki, K., Ito, R., Okada, M., Yoshioka, K., Uchide, T., Temma, K., et al. (2006). Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatment with doxorubicin in mice. Pharmacological Research., 53(4), 341–346.PubMedCrossRef

84.

Ivanová, M., Dovinová, I., Okruhlicová, Ľ, Tribulová, N., Šimončíková, P., Barte-ková, M., et al. (2012). Chronic cardiotoxicity of doxorubicin involves activation of myocardial and circulating matrix metalloproteinases in rats. Acta Pharmacologica Sinica., 33(4), 459–469. https://doi.org/10.1038/aps.2011.194CrossRefPubMedPubMedCentral

85.

Slezak, J., Kura, B., Babal, P., Barancik, M., Ferko, M., Frimmel, K., et al. (2017). Potential markers and metabolic processes involved in the mechanism of radiation-induced heart injury. Canadian Journal of Physiology and Pharmacology., 95(10), 1190–1203.PubMedCrossRef

86.

Bai, P., Mabley, J. G., Liaudet, L., Virág, L., Szabó, C., & Pacher, P. (2004). Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. Oncology Reports, 11(2), 505–508.PubMed

87.

O’Hanlon, R., Grasso, A., Roughton, M., Moon, J. C., Clark, S., Wage, R., et al. (2010). Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. Journal of the American College of Cardiology., 56(11), 867–874.PubMedCrossRef

88.

Liu, L. K., Ouyang, W., Zhao, X., Su, S. F., Yang, Y., Ding, W. J., et al. (2017). Pathogenesis and prevention of radiation-induced myocardial fibrosis. Asian Pacific Journal of Cancer Prevention: APJCP., 18(3), 583–587. https://doi.org/10.22034/APJCP.2017.18.3.583CrossRefPubMedPubMedCentral

89.

Nacif, M. S., Kawel, N., Lee, J. J., Chen, X., Yao, J., Zavodni, A., et al. (2012). Interstitial myocardial fibrosis assessed as extracellular volume fraction with low-radiation-dose cardiac CT. Radiology, 264(3), 876–883. https://doi.org/10.1148/radiol.12112458CrossRefPubMedPubMedCentral

90.

de Groot, C., Beukema, J. C., Langendijk, J. A., van der Laan, H. P., van Luijk, P., van Melle, J. P., et al. (2021). Radiation-induced myocardial fibrosis in long-term esophageal cancer survivors. International Journal of Radiation Oncology Biology Physics, 110(4), 1013–1021.PubMedCrossRef

91.

Farhad, H., Staziaki, P. V., Addison, D., Coelho-Filho, O. R., Shah, R. V., Mitchell, R. N., et al. (2016). Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging. Circulation Cardiovascular Imaging., 9(12), e003584. https://doi.org/10.1161/CIRCIMAGING.115.003584CrossRefPubMedPubMedCentral

92.

Tandri, H., Saranathan, M., Rodriguez, E. R., Martinez, C., Bomma, C., Nasir, K., et al. (2005). Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. Journal of the American College of Cardiology., 45(1), 98–103.PubMedCrossRef

93.

Iles, L., Pfluger, H., Phrommintikul, A., Cherayath, J., Aksit, P., Gupta, S. N., et al. (2008). Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. Journal of the American College of Cardiology., 52(19), 1574–1580. https://doi.org/10.1016/j.jacc.2008.06.049CrossRefPubMed

94.

Zhou, Z., Xu, L., Wang, R., Varga-Szemes, A., Durden, J. A., Joseph Schoepf, U., et al. (2019). Quantification of doxorubicin-induced interstitial myocardial fibrosis in a beagle model using equilibrium contrast-enhanced computed tomography: A comparative study with cardiac magnetic resonance T1-mapping. International Journal of Cardiology., 281, 150–155. https://doi.org/10.1016/j.ijcard.2019.01.021CrossRefPubMed

95.

Zhou, Z., Wang, R., Wang, H., Liu, Y., Lu, D., Sun, Z., et al. (2021). Myocardial extracellular volume fraction quantification in an animal model of the doxorubicin-induced myocardial fibrosis: A synthetic hematocrit method using 3T cardiac magnetic resonance. Quantitative Imaging in Medicine and Surgery., 11(2), 510–520. https://doi.org/10.21037/qims-20-501CrossRefPubMedPubMedCentral

96.

De Angelis, A., Urbanek, K., Cappetta, D., Piegari, E., Ciuffreda, L. P., Rivellino, A., et al. (2016). Doxorubicin cardiotoxicity and target cells: A broader perspective. Cardio-Oncology., 2(1), 1–8.CrossRef

97.

Piegari, E., De Angelis, A., Cappetta, D., Russo, R., Esposito, G., Costantino, S., et al. (2013). Doxorubicin induces senescence and impairs function of human cardiac progenitor cells. Basic Research in Cardiology., 108(2), 1–18.CrossRef

98.

Levick, S. P., Soto-Pantoja, D. R., Bi, J., Hundley, W. G., Widiapradja, A., Manteufel, E. J., et al. (2019). Doxorubicin-induced myocardial fibrosis involves the neurokinin-1 receptor and direct effects on cardiac fibroblasts. Heart, Lung & Circulation., 28(10), 1598–1605. https://doi.org/10.1016/j.hlc.2018.08.003CrossRef

99.

Najafi, M., Motevaseli, E., Shirazi, A., Geraily, G., Rezaeyan, A., Norouzi, F., et al. (2018). Mechanisms of inflammatory responses to radiation and normal tissues toxicity: Clinical implications. International Journal of Radiation Biology, 94(4), 335–356. https://doi.org/10.1080/09553002.2018.1440092CrossRefPubMed

100.

Farhood, B., Hoseini-Ghahfarokhi, M., Motevaseli, E., Mirtavoos-Mahyari, H., Musa, A. E., & Najafi, M. (2020). TGF-β in radiotherapy: Mechanisms of tumor resistance and normal tissues injury. Pharmacological Research., 155, 104745.PubMedCrossRef

101.

Amini, P., Rezapoor, S., Shabeeb, D., Musa, A. E., Najafi, M., & Motevaseli, E. (2018). Evaluating the protective effect of a combination of curcumin and selenium-L-methionine on radiation induced dual oxidase upregulation. Pharmaceutical Sciences., 24(4), 340–345.CrossRef

102.

Lin, F., Wang, N., & Zhang, T. C. (2012). The role of endothelial–mesenchymal transition in development and pathological process. IUBMB Life, 64(9), 717–723.PubMedCrossRef

103.

Song, S., Zhang, R., Cao, W., Fang, G., Yu, Y., Wan, Y., et al. (2019). Foxm1 is a critical driver of TGF-β-induced EndMT in endothelial cells through Smad2/3 and binds to the Snail promoter. Journal of Cellular Physiology., 234(6), 9052–9064.PubMedCrossRef

104.

Choi, K. J., Nam, J.-K., Kim, J.-H., Choi, S.-H., & Lee, Y.-J. (2020). Endothelial-to-mesenchymal transition in anticancer therapy and normal tissue damage. Experimental & Molecular Medicine., 52(5), 781–792.CrossRef

105.

Zhang, K., He, X., Zhou, Y., Gao, L., Qi, Z., Chen, J., et al. (2015). Atorvastatin ameliorates radiation-induced cardiac fibrosis in rats. Radiation Research, 184(6), 611–620. https://doi.org/10.1667/rr14075.1CrossRefPubMed

106.

Liu, H., Xiong, M., Xia, Y.-F., Cui, N.-J., Lu, R.-B., Deng, L., et al. (2009). Studies on pentoxifylline and tocopherol combination for radiation-induced heart disease in rats. International Journal of Radiation Oncology Biology Physics., 73(5), 1552–1559. https://doi.org/10.1016/j.ijrobp.2008.12.005CrossRefPubMed

107.

Tsai, T.-H., Lin, C.-J., Hang, C.-L., & Chen, W.-Y. (2019). Calcitriol attenuates doxorubicin-induced cardiac dysfunction and inhibits endothelial-to-mesenchymal transition in mice. Cells, 8(8), 865.PubMedCentralCrossRef

108.

Nie, L., Liu, M., Chen, J., Wu, Q., Li, Y., Yi, J., et al. (2021). Hydrogen sulfide ameliorates doxorubicin-induced myocardial fibrosis in rats via the PI3K/AKT/mTOR pathway. Molecular Medicine Reports, 23(4), 1–11.CrossRef

109.

Luo, L.-F., Guan, P., Qin, L.-Y., Wang, J.-X., Wang, N., & Ji, E.-S. (2021). Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling. Molecular and Cellular Biochemistry, 476(7), 2603–2611. https://doi.org/10.1007/s11010-021-04112-6CrossRefPubMed

110.

Arafa, M. H., Mohammad, N. S., Atteia, H. H., & Abd-Elaziz, H. R. (2014). Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. Journal of Physiology and Biochemistry, 70(3), 701–711.PubMedCrossRef

111.

Saleh, M. A., Antar, S. A., Hazem, R. M., & El-Azab, M. F. (2020). Pirfenidone and vitamin D ameliorate cardiac fibrosis induced by doxorubicin in ehrlich ascites carcinoma bearing mice: Modulation of monocyte chemoattractant protein-1 and Jun N-terminal kinase-1 pathways. Pharmaceuticals, 13(11), 348.PubMedCentralCrossRef

112.

Sahna, E., Parlakpinar, H., Ozer, M. K., Ozturk, F., Ozugurlu, F., & Acet, A. (2003). Melatonin protects against myocardial doxorubicin toxicity in rats: Role of physiological concentrations. Journal of Pineal Research, 35(4), 257–261.PubMedCrossRef

113.

Shaty, M. H., Arif, I. S., Al-Ezzi, M. I., & Hanna, D. B. (2018). Metformin attenuate fibrosis in both acute and chronic doxorubicin cardiotoxicity in rabbits. Journal of Pharmaceutical Sciences and Research, 10(6), 1559–1565.

114.

Katamura, M., Iwai-Kanai, E., Nakaoka, M., Okawa, Y., Ariyoshi, M., Mita, Y., et al. (2014). Curcumin attenuates doxorubicin-induced cardiotoxicity by inducing autophagy via the regulation of JNK phosphorylation. Journal of Clinical and Experimental Cardiology, 5(09), 1–8.CrossRef

115.

van der Veen, S. J., Ghobadi, G., de Boer, R. A., Faber, H., Cannon, M. V., Nagle, P. W., et al. (2015). ACE inhibition attenuates radiation-induced cardiopulmonary damage. Radiotherapy and Oncology, 114(1), 96–103. https://doi.org/10.1016/j.radonc.2014.11.017CrossRefPubMed

116.

Vatanen, A., Sarkola, T., Ojala, T. H., Turanlahti, M., Jahnukainen, T., Saarinen-Pihkala, U. M., et al. (2015). Radiotherapy-related arterial intima thickening and plaque formation in childhood cancer survivors detected with very-high resolution ultrasound during young adulthood. Pediatric Blood & Cancer, 62(11), 2000–2006.CrossRef

117.

Huang, T. L., Hsu, H. C., Chen, H. C., Lin, H. C., Chien, C. Y., Fang, F. M., et al. (2013). Long-term effects on carotid intima-media thickness after radiotherapy in patients with nasopharyngeal carcinoma. Radiation Oncology., 8(1), 1–6.CrossRef

118.

Schultz-Hector, S., & Trott, K. R. (2007). Radiation-induced cardiovascular diseases: Is the epidemiologic evidence compatible with the radiobiologic data? International Journal of Radiation Oncology Biology Physics, 67(1), 10–18. https://doi.org/10.1016/j.ijrobp.2006.08.071CrossRefPubMed

119.

Berliner, S., Rahima, M., Sidi, Y., Teplitsky, Y., Zohar, Y., Nussbaum, B., et al. (1990). Acute coronary events following cisplatin-based chemotherapy. Cancer Investigation, 8(6), 583–586.PubMedCrossRef

120.

Eckman, D. M., Stacey, R. B., Rowe, R., Dagostino, R., Jr., Kock, N. D., Sane, D. C., et al. (2013). Weekly doxorubicin increases coronary arteriolar wall and adventitial thickness. PLoS ONE, 8(2), e57554. https://doi.org/10.1371/journal.pone.0057554CrossRefPubMedPubMedCentral

121.

Vogelzang, N. J., Frenning, D. H., & Kennedy, B. J. (1980). Coronary artery disease after treatment with bleomycin and vinblastine. Cancer Treatment Reports, 64(10–11), 1159–1160.PubMed

122.

Stewart, F. A. (2012). Mechanisms and dose-response relationships for radiation-induced cardiovascular disease. Annals of the ICRP, 41(3–4), 72–79. https://doi.org/10.1016/j.icrp.2012.06.031CrossRefPubMed

123.

Khaled, S., Gupta, K. B., & Kucik, D. F. (2012). Ionizing radiation increases adhesiveness of human aortic endothelial cells via a chemokine-dependent mechanism. Radiation Research, 177(5), 594–601. https://doi.org/10.1667/rr2557.1CrossRefPubMed

124.

Haubner, F., Ohmann, E., Pohl, F., Prantl, L., Strutz, J., & Gassner, H. G. (2013). Effects of radiation on the expression of adhesion molecules and cytokines in a static model of human dermal microvascular endothelial cells. Clinical Hemorheology and Microcirculation, 54(4), 371–379. https://doi.org/10.3233/ch-2012-1626CrossRefPubMed

125.

Cuomo, J. R., Javaheri, S. P., Sharma, G. K., Kapoor, D., Berman, A. E., & Weintraub, N. L. (2018). How to prevent and manage radiation-induced coronary artery disease. Heart, 104(20), 1647–1653. https://doi.org/10.1136/heartjnl-2017-312123CrossRefPubMed

126.

Hoving, S., Heeneman, S., Gijbels, M. J., te Poele, J. A., Russell, N. S., Daemen, M. J., et al. (2008). Single-dose and fractionated irradiation promote initiation and progression of atherosclerosis and induce an inflammatory plaque phenotype in ApoE(-/-) mice. International Journal of Radiation Oncology Biology Physics, 71(3), 848–857. https://doi.org/10.1016/j.ijrobp.2008.02.031CrossRefPubMed

127.

Basavaraju, S. R., & Easterly, C. E. (2002). Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Medical Physics, 29(10), 2391–2403. https://doi.org/10.1118/1.1509442CrossRefPubMed

128.

He, F., & Zuo, L. (2015). Redox roles of reactive oxygen species in cardiovascular diseases. International Journal of Molecular Sciences, 16(11), 27770–27780. https://doi.org/10.3390/ijms161126059CrossRefPubMedPubMedCentral

129.

Pfenniger, A., Chanson, M., & Kwak, B. R. (2013). Connexins in atherosclerosis. Biochimica et Biophysica Acta, 1828(1), 157–166. https://doi.org/10.1016/j.bbamem.2012.05.011CrossRefPubMed

130.

Ohshima, Y., Tsukimoto, M., Harada, H., & Kojima, S. (2012). Involvement of connexin43 hemichannel in ATP release after γ-irradiation. Journal of Radiation Research, 53(4), 551–557. https://doi.org/10.1093/jrr/rrs014CrossRefPubMedPubMedCentral

131.

Carta, S., Castellani, P., Delfino, L., Tassi, S., Vene, R., & Rubartelli, A. (2009). DAMPs and inflammatory processes: The role of redox in the different outcomes. Journal of Leukocyte Biology, 86(3), 549–555.PubMedCrossRef

132.

Ramadan, R., Baatout, S., Aerts, A., & Leybaert, L. (2021). The role of connexin proteins and their channels in radiation-induced atherosclerosis. Cellular and Molecular Life Sciences., 78(7), 3087–3103. https://doi.org/10.1007/s00018-020-03716-3CrossRefPubMedPubMedCentral

133.

Ramadan, R., Vromans, E., Anang, D. C., Goetschalckx, I., Hoorelbeke, D., Decrock, E., et al. (2020). Connexin43 hemichannel targeting with TAT-Gap19 alleviates radiation-induced endothelial cell damage. Frontiers in Pharmacology., 11, e00212. https://doi.org/10.3389/fphar.2020.00212CrossRef

134.

Viczenczova, C., Kura, B., Egan Benova, T., Yin, C., Kukreja, R. C., Slezak, J., et al. (2018). Irradiation-induced cardiac connexin-43 and miR-21 responses are hampered by treatment with atorvastatin and aspirin. International Journal of Molecular Sciences, 19(4), 1128. https://doi.org/10.3390/ijms19041128CrossRefPubMedCentral

135.

Sato, A., Yoshihisa, A., Miyata-Tatsumi, M., Oikawa, M., Kobayashi, A., Ishida, T., et al. (2019). Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxicity in patients with breast cancer. Molecular and Clinical Oncology, 10(1), 37–42.PubMed

136.

Cella, L., Oh, J. H., Deasy, J. O., Palma, G., Liuzzi, R., D’avino, V., et al. (2015). Predicting radiation-induced valvular heart damage. Acta Oncologica., 54(10), 1796–1804.PubMedCrossRef

137.

Bijl, J. M., Roos, M. M., van Leeuwen-Segarceanu, E. M., Vos, J. M., Bos, W.-J.W., Biesma, D. H., et al. (2016). Assessment of valvular disorders in survivors of Hodgkin’s lymphoma treated by mediastinal radiotherapy±chemotherapy. The American Journal of Cardiology., 117(4), 691–696.PubMedCrossRef

138.

Gujral, D. M., Lloyd, G., & Bhattacharyya, S. (2016). Radiation-induced valvular heart disease. Heart, 102(4), 269–276.PubMedCrossRef

139.

Nadlonek, N. A., Weyant, M. J., Jessica, A. Y., Cleveland, J. C., Jr., Reece, T. B., Meng, X., et al. (2012). Radiation induces osteogenesis in human aortic valve interstitial cells. The Journal of Thoracic and Cardiovascular Surgery., 144(6), 1466–1470.PubMedPubMedCentralCrossRef

140.

Wang, H., Wei, J., Zheng, Q., Meng, L., Xin, Y., Yin, X., et al. (2019). Radiation-induced heart disease: A review of classification, mechanism and prevention. International Journal of Biological Sciences, 15(10), 2128–2138. https://doi.org/10.7150/ijbs.35460CrossRefPubMedPubMedCentral

141.

Barrick, C. J., Roberts, R. B., Rojas, M., Rajamannan, N. M., Suitt, C. B., O’Brien, K. D., et al. (2009). Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice. American Journal of Physiology-Heart and Circulatory Physiology., 297(1), H65–H75.PubMedPubMedCentralCrossRef

142.

Gorini, S., De Angelis, A., Berrino, L., Malara, N., Rosano, G., & Ferraro, E. (2018). Chemotherapeutic drugs and mitochondrial dysfunction: Focus on doxorubicin, trastuzumab, and sunitinib. Oxidative Medicine and Cellular Longevity, 2018, 7582730. https://doi.org/10.1155/2018/7582730CrossRefPubMedPubMedCentral

143.

Grazette, L. P., Boecker, W., Matsui, T., Semigran, M., Force, T. L., Hajjar, R. J., et al. (2004). Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: Implications for herceptin-induced cardiomyopathy. Journal of the American College of Cardiology., 44(11), 2231–2238. https://doi.org/10.1016/j.jacc.2004.08.066CrossRefPubMed

144.

Sun, L., Wang, H., Yu, S., Zhang, L., Jiang, J., & Zhou, Q. (2022). Herceptin induces ferroptosis and mitochondrial dysfunction in H9c2 cells. International Journal of Molecular Medicine, 49(2), 17. https://doi.org/10.3892/ijmm.2021.5072CrossRefPubMed

145.

Karabay, C. Y., Kocabay, G., Kalayci, A., Zehir, R., & Tanboga, H. (2010). Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment. Cardiology, 117(4), 296–300. https://doi.org/10.1159/000323834CrossRefPubMed

146.

Fortuni, F., Bax, J. J., & Delgado, V. (2021). Changing the paradigm in the management of valvular heart disease. Circulation, 143(3), 209–211. https://doi.org/10.1161/CIRCULATIONAHA.120.050763CrossRefPubMed

147.

Grela-Wojewoda, A., Niemiec, J., Sas-Korczyńska, B., Zemełka, T., Puskulluoglu, M., & Wysocki, W. M. et al. (2022). Adjuvant combined therapy with trastuzumab in patients with HER2-positive breast cancer and cardiac alterations: Implications for optimal cardio-oncology care. Polish Archives of Internal Medicine.

148.

Ewer, S. M., & Ewer, M. S. (2008). Cardiotoxicity profile of trastuzumab. Drug Safety, 31(6), 459–467.PubMedCrossRef

149.

Guarneri, V., Lenihan, D. J., Valero, V., Durand, J. B., Broglio, K., Hess, K. R., et al. (2006). Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience. Journal of Clinical Oncology, 24(25), 4107–15. https://doi.org/10.1200/jco.2005.04.9551CrossRefPubMed

150.

Saiki, H., Moulay, G., Guenzel, A. J., Liu, W., Decklever, T. D., Classic, K. L., et al. (2017). Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction. American Journal of Physiology-Heart and Circulatory Physiology., 313(2), H392–H407.PubMedPubMedCentralCrossRef

151.

Dobaczewski, M., Chen, W., & Frangogiannis, N. G. (2011). Transforming growth factor (TGF)-β signaling in cardiac remodeling. Journal of Molecular and Cellular Cardiology, 51(4), 600–606. https://doi.org/10.1016/j.yjmcc.2010.10.033CrossRefPubMed

152.

Monceau, V., Meziani, L., Strup-Perrot, C., Morel, E., Schmidt, M., Haagen, J., et al. (2013). Enhanced sensitivity to low dose irradiation of ApoE-/- mice mediated by early pro-inflammatory profile and delayed activation of the TGFβ1 cascade involved in fibrogenesis. PLoS ONE, 8(2), e57052. https://doi.org/10.1371/journal.pone.0057052CrossRefPubMedPubMedCentral

153.

Luk, A., Ahn, E., Soor, G. S., & Butany, J. (2009). Dilated cardiomyopathy: A review. Journal of Clinical Pathology., 62(3), 219–225.PubMedCrossRef

154.

Cuomo, J. R., Sharma, G. K., Conger, P. D., & Weintraub, N. L. (2016). Novel concepts in radiation-induced cardiovascular disease. World Journal of Cardiology, 8(9), 504–519. https://doi.org/10.4330/wjc.v8.i9.504CrossRefPubMedPubMedCentral

155.

Harvey, P. A., & Leinwand, L. A. (2011). The cell biology of disease: Cellular mechanisms of cardiomyopathy. The Journal of Cell Biology., 194(3), 355–365. https://doi.org/10.1083/jcb.201101100CrossRefPubMedPubMedCentral

156.

Maisel, W. H., & Stevenson, L. W. (2003). Atrial fibrillation in heart failure: Epidemiology, pathophysiology, and rationale for therapy. The American Journal of Cardiology., 91(6), 2–8.CrossRef

157.

Stevenson, W. G., & Stevenson, L. W. (1999). Atrial fibrillation in heart failure (pp. 910–911). Waltham: Mass Medical Soc.

158.

O’Neal, W. T., Lakoski, S. G., Qureshi, W., Judd, S. E., Howard, G., Howard, V. J., et al. (2015). Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study). The American Journal of Cardiology., 115(8), 1090–1094.PubMedPubMedCentralCrossRef

159.

Yang, X., Li, X., Yuan, M., Tian, C., Yang, Y., Wang, X., et al. (2018). Anticancer therapy-induced atrial fibrillation: Electrophysiology and related mechanisms. Frontiers in Pharmacology., 9, 1058. https://doi.org/10.3389/fphar.2018.01058CrossRefPubMedPubMedCentral

160.

Grandi, E., & Herren, A. (2014). CaMKII-dependent regulation of cardiac Na+ homeostasis. Frontiers in Pharmacology., 5, 41. https://doi.org/10.3389/fphar.2014.00041CrossRefPubMedPubMedCentral

161.

Strigli, A., Raab, C., Hessler, S., Huth, T., Schuldt, A. J. T., Alzheimer, C., et al. (2018). Doxorubicin induces caspase-mediated proteolysis of KV7.1. Communications Biology, 1(1), 155. https://doi.org/10.1038/s42003-018-0162-zCrossRefPubMedPubMedCentral

162.

Swaminathan, P. D., Purohit, A., Hund, T. J., & Anderson, M. E. (2012). Calmodulin-dependent protein kinase II: Linking heart failure and arrhythmias. Circulation Research., 110(12), 1661–1677. https://doi.org/10.1161/CIRCRESAHA.111.243956CrossRefPubMedPubMedCentral

163.

Greer-Short, A., Musa, H., Alsina, K. M., Ni, L., Word, T. A., Reynolds, J. O., et al. (2020). Calmodulin kinase II regulates atrial myocyte late sodium current, calcium handling, and atrial arrhythmia. Heart Rhythm, 17(3), 503–511. https://doi.org/10.1016/j.hrthm.2019.10.016CrossRefPubMed

164.

Benjanuwattra, J., Siri-Angkul, N., Chattipakorn, S. C., & Chattipakorn, N. (2020). Doxorubicin and its proarrhythmic effects: A comprehensive review of the evidence from experimental and clinical studies. Pharmacological Research., 151, 104542.PubMedCrossRef

165.

McMullen, J. R., Boey, E. J. H., Ooi, J. Y. Y., Seymour, J. F., Keating, M. J., & Tam, C. S. (2014). Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood, 124(25), 3829–3830. https://doi.org/10.1182/blood-2014-10-604272CrossRefPubMed

166.

Zhao, L. (2019). Protective effects of trimetazidine and coenzyme Q10 on cisplatin-induced cardiotoxicity by alleviating oxidative stress and mitochondrial dysfunction. Anatolian Journal of Cardiology., 22(5), 232.PubMedPubMedCentral

167.

Darling, H. (2015). Cisplatin induced bradycardia. International Journal of Cardiology., 182, 304–306.PubMedCrossRef

Title: Cardiac Remodelling Following Cancer Therapy: A Review
Authors: Tan Panpan
Du Yuchen
Shi Xianyong
Liu Meng
He Ruijuan
Dong Ranran
Zhang Pengyan
Li Mingxi
Xie Rongrong
Publication date: 25-07-2022
Publisher: Springer US
Keywords: Cardiomyopathy
Ionizing Radiation
Myocarditis
Valvular Heart Disease
Cancer Therapy
Cytostatic Therapy
Published in: Cardiovascular Toxicology / Issue 9/2022
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-022-09762-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Cardiac Remodelling Following Cancer Therapy: A Review

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2022

Maternal Ethanol Exposure-Induced Cardiac Fibrosis is Associated with Changes in TGF-β and SIRT1/FOXO3a Signaling in Male Rat Offspring: A Three-Month Follow-up Study

l-Carnitine Mitigates Trazadone Induced Rat Cardiotoxicity Mediated via Modulation of Autophagy and Oxidative Stress

LncRNA MALAT1 Regulates USP22 Expression Through EZH2-Mediated H3K27me3 Modification to Accentuate Sepsis-Induced Myocardial Dysfunction

An Improved Monkey Model of Myocardial Ischemic Infarction for Cardiovascular Drug Development

Salvianolic Acid B Alleviates Myocardial Ischemia Injury by Suppressing NLRP3 Inflammasome Activation via SIRT1-AMPK-PGC-1α Signaling Pathway

QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with “Known Risk of Torsades de Pointes”

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page